Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Analysts

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have received a consensus rating of “Hold” from the five analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $17.00.

A number of research firms recently commented on VRCA. raised shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a report on Thursday, December 18th. Loop Capital set a $17.00 price objective on Verrica Pharmaceuticals in a report on Thursday, December 18th. Zacks Research downgraded Verrica Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 9th. Wall Street Zen lowered Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, January 7th.

Verrica Pharmaceuticals Stock Performance

NASDAQ VRCA opened at $5.45 on Monday. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82. The company has a 50-day simple moving average of $6.43 and a 200 day simple moving average of $5.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.45 and a current ratio of 2.59. The company has a market capitalization of $93.63 million, a PE ratio of -3.45 and a beta of 1.47.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Wednesday, March 11th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). The business had revenue of $5.09 million for the quarter, compared to analyst estimates of $4.52 million. On average, research analysts predict that Verrica Pharmaceuticals will post -1.46 EPS for the current year.

Institutional Trading of Verrica Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. State Street Corp boosted its holdings in Verrica Pharmaceuticals by 14.1% in the 4th quarter. State Street Corp now owns 23,481 shares of the company’s stock worth $195,000 after buying an additional 2,900 shares during the period. Man Group plc bought a new stake in Verrica Pharmaceuticals during the 4th quarter valued at $94,000. Quadrature Capital Ltd purchased a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth $99,000. Beck Mack & Oliver LLC purchased a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth $100,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Verrica Pharmaceuticals in the third quarter worth $52,000. 42.45% of the stock is currently owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.